Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.

Sophie Lehn; Nicholas P Tobin; Andrew H Sims; Olle Stål; Karin Jirström; Håkan Axelson; Göran Landberg

doi:10.1186/1471-2407-14-119

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.

Sophie Lehn, Nicholas P Tobin, Andrew H Sims, Olle Stål, Karin Jirström, Håkan Axelson, Göran Landberg

Research output: Contribution to journal › Article › peer-review

278 Downloads (Pure)

Abstract

Yes-associated protein (YAP1) is frequently reported to function as an oncogene in many types of cancer, but in breast cancer results remain controversial. We set out to clarify the role of YAP1 in breast cancer by examining gene and protein expression in subgroups of patient material and by downregulating YAP1 in vitro and studying its role in response to the widely used anti-estrogen tamoxifen.

Original language	English
Article number	119
Journal	BMC Cancer
Volume	14
Issue number	1
DOIs	https://doi.org/10.1186/1471-2407-14-119
Publication status	Published - 2014

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Molecular pathology (013031700), Pathology, (Lund) (013030000), Division of Translational Cancer Research (013250500), Pathology (Malmö) (013031000)

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1471-2407-14-119

BMC_Lehn_et_al

http://www.ncbi.nlm.nih.gov/pubmed/24559095?dopt=Abstract

Cite this

@article{dbbaedb4e77045a5a85063cead7f763e,

title = "Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.",

abstract = "Yes-associated protein (YAP1) is frequently reported to function as an oncogene in many types of cancer, but in breast cancer results remain controversial. We set out to clarify the role of YAP1 in breast cancer by examining gene and protein expression in subgroups of patient material and by downregulating YAP1 in vitro and studying its role in response to the widely used anti-estrogen tamoxifen.",

author = "Sophie Lehn and Tobin, {Nicholas P} and Sims, {Andrew H} and Olle St{\aa}l and Karin Jirstr{\"o}m and H{\aa}kan Axelson and G{\"o}ran Landberg",

note = "The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Molecular pathology (013031700), Pathology, (Lund) (013030000), Division of Translational Cancer Research (013250500), Pathology (Malm{\"o}) (013031000)",

year = "2014",

doi = "10.1186/1471-2407-14-119",

language = "English",

volume = "14",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central (BMC)",

number = "1",

}

TY - JOUR

T1 - Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.

AU - Lehn, Sophie

AU - Tobin, Nicholas P

AU - Sims, Andrew H

AU - Stål, Olle

AU - Jirström, Karin

AU - Axelson, Håkan

AU - Landberg, Göran

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Molecular pathology (013031700), Pathology, (Lund) (013030000), Division of Translational Cancer Research (013250500), Pathology (Malmö) (013031000)

PY - 2014

Y1 - 2014

N2 - Yes-associated protein (YAP1) is frequently reported to function as an oncogene in many types of cancer, but in breast cancer results remain controversial. We set out to clarify the role of YAP1 in breast cancer by examining gene and protein expression in subgroups of patient material and by downregulating YAP1 in vitro and studying its role in response to the widely used anti-estrogen tamoxifen.

AB - Yes-associated protein (YAP1) is frequently reported to function as an oncogene in many types of cancer, but in breast cancer results remain controversial. We set out to clarify the role of YAP1 in breast cancer by examining gene and protein expression in subgroups of patient material and by downregulating YAP1 in vitro and studying its role in response to the widely used anti-estrogen tamoxifen.

U2 - 10.1186/1471-2407-14-119

DO - 10.1186/1471-2407-14-119

M3 - Article

C2 - 24559095

SN - 1471-2407

VL - 14

JO - BMC Cancer

JF - BMC Cancer

IS - 1

M1 - 119

ER -

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.

Abstract

Bibliographical note

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this